NewsBenzingaLigand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M Est Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M Est Benzinga 2026.10.29 11:02 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients